Results 101 to 110 of about 42,556 (220)

Autophagy Modulation in Cancer Therapy: Navigating the Dual Roles to Overcome Chemoresistance

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background Autophagy is a fundamental cellular recycling mechanism with complex and often opposing roles in cancer, functioning as both a tumor suppressor and a pro‐survival mechanism in established tumors. This duality has attracted considerable attention, particularly regarding the therapeutic modulation of autophagy to overcome ...
Md Mohiuddin, Md Al Mamun Ahsan
wiley   +1 more source

Urokinase Plasminogen Activator Receptor‐Associated Protein (uPARAP) as a Potential Next Generation Molecular Target for Treatment of Gastrointestinal Stromal Tumors (GIST)

International Journal of Cancer, Volume 159, Issue 3, Page 797-808, 1 August 2026.
A key component of the collagen internalization and lysosomal degradation cellular machinery, uPARAP may contribute to cancer progression. Here, the authors explored the expression of uPARAP in gastrointestinal stromal tumors using well‐annotated clinical patient samples and specimens from cell line‐ and patient‐derived xenografts.
Chao‐Chi Wang, Flavia Paternostro, Agnieszka Wozniak, Lore De Cock, Luna De Sutter, Kimberly Verbeeck, Ulla Vanleeuw, Daniël Gorgels, Che‐Jui Lee, Raf Sciot, Patrick Schöffski   +10 more
wiley   +1 more source

Development and Release of the Munich UICC Staging Tool (MUST): Advancing UICC Staging in Real‐World Data With Insights From Pancreatic and Stomach Cancer

International Journal of Cancer, Volume 159, Issue 3, Page 757-767, 1 August 2026.
Accurate cancer staging is essential for cancer research and treatment evaluation. However, real‐world data often include incomplete or inconsistent UICC staging classifications. The presented Munich UICC Staging Tool (MUST) automates UICC stage derivation from TNM classifications and tumor characteristics, incorporating novel real‐world data rules to ...
Brigitte Kühnel, Sophie Schneiderbauer, Sebastian Lange, Dirk Wilhelm, Helmut Friess, Marcus Feith, Ursula Ehmer, Florian Bassermann, Julian W. Holch, Stefan M. Munker, Jens Neumann, Jens Werner, Hubert J. Stein, Theres Fey, Ulrich Mansmann, Hana Algül, Karin Berger‐Thürmel, H. Carlo Maurer, Daniel Nasseh   +18 more
wiley   +1 more source

Tumor Plasticity and Microenvironmental Crosstalk as Drivers of Metastasis and Therapy Resistance

MedComm, Volume 7, Issue 8, August 2026.
The graphical abstract is a schematic illustration of the bidirectional crosstalk between tumor plasticity and the tumor microenvironment (TME) in driving metastasis and therapy resistance. Tumor‐intrinsic factors such as genetic mutations and epigenetic reprogramming enable dynamic transitions between epithelial, mesenchymal, and cancer stem cell ...
Gunjan Dagar, Manisha Dagar, Ashna Gupta, Anju Surendranath, Suraja Kumar Das, Mohd Umar Rehmani, Mukesh Tanwar, Sameer Mirza, Muzafar A. Macha, Ammira S. Al‐Shabeeb Akil, Shahab Uddin, Mayank Singh, Ajaz A. Bhat   +12 more
wiley   +1 more source

Successful Diagnostic Confirmation of Malignant Pleural Mesothelioma With Extensive Pleural Adhesions Using Pleural Cryobiopsy Under Local Anaesthesia

Respirology Case Reports, Volume 14, Issue 8, August 2026.
Pleural cryobiopsy under local anaesthesia enabled definitive diagnosis of malignant pleural mesothelioma despite extensive pleural adhesions. Careful preoperative assessment and precise lesion localisation allowed safe and minimally invasive tissue acquisition in a high‐risk patient.
Shotaro Otaki, Mikito Suzuki, Kaito Yano, Tomohiro Imoto, Reiko Shimizu, Tsunekazu Hishima, Kazuo Nakagawa   +6 more
wiley   +1 more source

Consumed by Abdominal Distention

Arthritis Care &Research, Volume 78, Issue 8, Page 959-966, August 2026.
Abimbola Fadairo‐Azinge, James Grenert, Brian Haas, Mary Margaretten   +3 more
wiley   +1 more source

Insights Into Genomic Drivers, Transcriptomic Heterogeneity, and Therapeutic Vulnerabilities From Novel Mesothelioma Cell Lines

Thoracic Cancer, Volume 17, Issue 15, August 2026.
Three novel malignant pleural mesothelioma (MPM) cell lines (PUMC‐MESO1, PUMC‐MESO3, and PUMC‐MESO4) were established from patient‐derived pleural effusions. All three cell lines expressed mesothelioma markers (calretinin, WT1, and D2‐40) and showed BAP1 loss of expression.
Yani Wu, Fang Cao, Jiayin Dai, Zhenli Yang, Yanli Zhu, Dongmei Lin, Xiaocui Bian, Yuqin Liu   +7 more
wiley   +1 more source

Antigen targeting and anti-tumor activity of a novel anti-CD146 212Pb internalizing alpha-radioimmunoconjugate against malignant peritoneal mesothelioma

Scientific Reports
Malignant mesothelioma, a highly aggressive cancer that primarily affects the serosal membranes, has limited therapeutic options, particularly for cavitary tumors, such as peritoneal and pleural malignant mesothelioma.
Kim Lindland, Marion Masitsa Malenge, Ruth Gong Li, Roxanne Wouters, Tina Bjørnlund Bønsdorff, Asta Juzeniene, Srdan M. Dragovic   +6 more
doaj   +1 more source

Standardization of postoperative adverse event reporting: A critical opportunity for improvement within the National Clinical Trials Network

Cancer, Volume 132, Issue 15, 1 August 2026.
Beth Helmink, Matthew H. G. Katz, Chandrajit P. Raut, Sumithra J. Mandrekar, Kristina Laumann, Allison Booth, Laura Hoffman, Eric A. Singer, Isabelle Bedrosian, Rebecca A. Snyder   +9 more
wiley   +1 more source

Advanced Thymoma and Advanced Thymic Carcinoma Treatment Practices in 2018–2022: A Nationwide Analysis in Japan

Thoracic Cancer, Volume 17, Issue 15, August 2026.
In the field of rare diseases, where high‐quality evidence remains limited, this study demonstrated how controversial treatment practices are managed in real‐world settings on a nationwide scale. The proportion of anthracycline‐based chemotherapy for stage IV thymoma increased from 50.0% in 2018 to 77.8% in 2022.
Junichi Ishigaki, Ryoko Rikitake, Hidenori Kage, Takahiro Higashi   +3 more
wiley   +1 more source